Literature DB >> 15015649

The characteristics of acute rejection after limb allotransplantation in rats--an experimental study.

Hao Kang1, Guangxiang Hong, Fabin Wang, Zhenbing Chen, Qishun Huang, Yuxiong Weng.   

Abstract

To study the characteristics of acute rejection after limb allotransplantation, 29 male Sprague-Dawley rats were randomly divided into 2 groups, with 15 rats in control group and 14 rats in experimental group. Each rat in control group underwent limb replantation. Each rat in experimental group received limb transplantation from Wistar rat. No immunosuppressive drugs were used after operation. The circulation of the transplanted limb, time and signs of rejection, histopathological changes in the tissues of the limb graft when rejected and survival time of limb grafts were evaluated. In the control group, no signs of rejection were observed, the circulation of each replanted limb was normal, it could survive for a longer time. The experimental group showed clinical signs of rejection (sub dermal edema and erythema) after a mean time of 3.36+/-1.15 days, and the mean survival time of the allografts was only 7+/-0.78 days. Histopathological examination showed most violent rejection reaction in skin. It is concluded that with Wistar-to-SD limb transplantation without use of immunosuppression, rejection of the grafts would occur after a mean time of 3.36+/-1.15 days; the earliest signs of rejection were edema and erythema of the skin, skin being the most representative component of limb graft rejection.

Entities:  

Mesh:

Year:  2003        PMID: 15015649     DOI: 10.1007/BF02829431

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  13 in total

1.  A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation.

Authors:  M E Billingham; N R Cary; M E Hammond; J Kemnitz; C Marboe; H A McCallister; D C Snovar; G L Winters; A Zerbe
Journal:  J Heart Transplant       Date:  1990 Nov-Dec

2.  Relative antigenicity of components of a vascularized limb allograft.

Authors:  W P Lee; M J Yaremchuk; Y C Pan; M A Randolph; C M Tan; A J Weiland
Journal:  Plast Reconstr Surg       Date:  1991-03       Impact factor: 4.730

3.  Experimental studies of vascularized allogeneic limb transplantation in the rat using a new immunosuppressive agent, FK-506: morphological and immunological analysis.

Authors:  H Kuroki; Y Ikuta; M Akiyama
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

4.  Functional recovery in the rat limb transplant model: a preliminary study.

Authors:  G Guzman-Stein; A R Shons
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

5.  Canine limb homotransplantation.

Authors:  R M Goldwyn; P M Beach; D Feldman; R E Wilson
Journal:  Plast Reconstr Surg       Date:  1966-03       Impact factor: 4.730

6.  Use of cyclosporin A in allotransplantation of rat limbs.

Authors:  S K Kim; S Aziz; P Oyer; V R Hentz
Journal:  Ann Plast Surg       Date:  1984-03       Impact factor: 1.539

7.  Limb allografts in rats immunosuppressed with cyclosporin A.

Authors:  W D Fritz; W M Swartz; S Rose; J W Futrell; E Klein
Journal:  Ann Surg       Date:  1984-02       Impact factor: 12.969

8.  Composite tissue (limb) allografts in rats. II. Indefinite survival using low-dose cyclosporine.

Authors:  K S Black; C W Hewitt; L A Fraser; E B Howard; D C Martin; B M Achauer; D W Furnas
Journal:  Transplantation       Date:  1985-04       Impact factor: 4.939

9.  Rejection of the component tissues of limb allografts in rats immunosuppressed with FK-506 and cyclosporine.

Authors:  R Büttemeyer; N F Jones; Z Min; U Rao
Journal:  Plast Reconstr Surg       Date:  1996-01       Impact factor: 4.730

10.  Homotransplantation of limbs in rats. A preliminary report on an experimental study with nonspecific immunosuppressive drugs.

Authors:  K Doi
Journal:  Plast Reconstr Surg       Date:  1979-11       Impact factor: 4.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.